TR200201920T2 - İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri. - Google Patents
İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri.Info
- Publication number
- TR200201920T2 TR200201920T2 TR2002/01920T TR200201920T TR200201920T2 TR 200201920 T2 TR200201920 T2 TR 200201920T2 TR 2002/01920 T TR2002/01920 T TR 2002/01920T TR 200201920 T TR200201920 T TR 200201920T TR 200201920 T2 TR200201920 T2 TR 200201920T2
- Authority
- TR
- Turkey
- Prior art keywords
- binding
- receptors
- inhibit
- integrins
- carboxylic acid
- Prior art date
Links
- 102000005962 receptors Human genes 0.000 title abstract 2
- 108020003175 receptors Proteins 0.000 title abstract 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Alfa4beta1 integrinin reseptörlerine, örnegin VCAM-1'e (vaskular hücre yapisma molekülü-1) ve fibronektine baglanmasinin engellenmesi için bir yöntem; bu baglanmayi engelleyen bilesikler; bu bilesikleri içeren farmasötik açidan aktif bilesimler; ve bu bilesiklerin, ya yukaridaki sekilde ya da formülasyon içinde, alfa4beta1'in katildigi hastalik durumlarinin kontrolü ya da engellenmesi için kullanimi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13297199P | 1999-05-07 | 1999-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200201920T2 true TR200201920T2 (tr) | 2002-09-23 |
Family
ID=22456441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/01920T TR200201920T2 (tr) | 1999-05-07 | 2000-05-05 | İntegrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri. |
| TR2001/03178T TR200103178T2 (tr) | 1999-05-07 | 2000-05-05 | İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/03178T TR200103178T2 (tr) | 1999-05-07 | 2000-05-05 | İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri. |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1176956B1 (tr) |
| JP (1) | JP5132855B2 (tr) |
| AT (1) | ATE383153T1 (tr) |
| AU (1) | AU5267900A (tr) |
| CA (1) | CA2373360C (tr) |
| CY (1) | CY1107438T1 (tr) |
| CZ (1) | CZ303312B6 (tr) |
| DE (1) | DE60037726T2 (tr) |
| DK (1) | DK1176956T3 (tr) |
| ES (1) | ES2296625T3 (tr) |
| IL (2) | IL146311A0 (tr) |
| IN (1) | IN2001KN01110A (tr) |
| MX (1) | MXPA01011340A (tr) |
| NO (1) | NO324421B1 (tr) |
| NZ (1) | NZ515248A (tr) |
| PL (1) | PL205322B1 (tr) |
| RO (1) | RO122246B1 (tr) |
| RU (1) | RU2263109C2 (tr) |
| SI (1) | SI20744B (tr) |
| SK (1) | SK286696B6 (tr) |
| TR (2) | TR200201920T2 (tr) |
| WO (1) | WO2000067746A1 (tr) |
| ZA (1) | ZA200108774B (tr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| US6723711B2 (en) * | 1999-05-07 | 2004-04-20 | Texas Biotechnology Corporation | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| AR026748A1 (es) | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
| SI21096B (sl) * | 2001-10-09 | 2012-05-31 | Encysive Pharmaceuticals Inc | Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje |
| ES2334990T3 (es) * | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
| BR0312232A (pt) | 2002-06-28 | 2005-05-10 | Vertex Pharma | Inibidores de caspases e seus usos |
| US7122580B2 (en) | 2002-08-09 | 2006-10-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| AU2003291362B2 (en) * | 2002-11-08 | 2009-01-15 | Schering Corporation | Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds |
| EP1581501A1 (en) | 2002-12-20 | 2005-10-05 | Vertex Pharmaceuticals Incorporated | 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors |
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2007022964A2 (de) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| WO2008109991A1 (en) * | 2007-03-09 | 2008-09-18 | University Health Network | Inhibitors of carnitine palmitoyltransferase and treating cancer |
| CA2677049A1 (en) | 2007-08-01 | 2009-02-05 | Sionex Corporation | Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| EP2424841A1 (en) * | 2009-04-27 | 2012-03-07 | Elan Pharmaceuticals Inc. | Pyridinone antagonists of alpha-4 integrins |
| WO2012033548A2 (en) * | 2010-09-07 | 2012-03-15 | E. I. Du Pont De Nemours And Company | Herbicidal bis-nitrogen-containing oxo and sulfono heterocycles |
| AU2010292400B2 (en) | 2009-09-09 | 2016-09-08 | Fmc Corporation | Herbicidal pyrimidone derivatives |
| MY165215A (en) * | 2012-01-31 | 2018-03-09 | Daiichi Sankyo Co Ltd | Pyridone derivatives |
| AU2014321397C1 (en) | 2013-09-20 | 2019-08-01 | Biomarin Pharmaceutical Inc. | Glucosylceramide synthase inhibitors for the treatment of diseases |
| US20170002077A1 (en) | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
| US10233195B2 (en) * | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| US10875875B2 (en) * | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| US10246451B2 (en) * | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
| KR20200018407A (ko) | 2017-04-28 | 2020-02-19 | 텍사스 칠드런스 하스피탈 | 표적화 나노입자 |
| ES2949662T3 (es) * | 2018-02-02 | 2023-10-02 | Genentech Inc | Compuesto farmacéutico, sales del mismo, formulaciones del mismo y métodos de fabricación y uso del mismo |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| CN114222730B (zh) | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2614189A1 (de) * | 1976-04-02 | 1977-10-20 | Hoechst Ag | Therapeutisch wirksame ureido- und semicarbazido-derivate des tiazols und verfahren zu ihrer herstellung |
| US5220017A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
| US5721366A (en) * | 1993-03-31 | 1998-02-24 | G. D. Searle & Co | Platelet aggregation inhibitors |
| AU672699B2 (en) * | 1993-06-30 | 1996-10-10 | Sankyo Company Limited | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses |
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| JPH07304755A (ja) * | 1994-05-12 | 1995-11-21 | Yamanouchi Pharmaceut Co Ltd | 縮合ジアゼピン誘導体 |
| US5610296A (en) * | 1994-12-05 | 1997-03-11 | G. D. Searle & Co. | Process for the preparation of amidino phenyl pyrrolidine beta-alanine urea analogs |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| DE69708102T2 (de) * | 1996-05-15 | 2002-07-11 | G.D. SEARLE & CO., CHICAGO | Verfahren und reagenz zur überwachung des blutspiegels von antiplättchen-verbindungen |
| WO1998011896A1 (en) * | 1996-09-18 | 1998-03-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| US6025358A (en) * | 1998-06-11 | 2000-02-15 | G. D. Searle & Co. | Double prodrugs of potent GP IIb/IIIa antagonists |
| US6630488B1 (en) * | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
-
2000
- 2000-05-05 AU AU52679/00A patent/AU5267900A/en not_active Abandoned
- 2000-05-05 AT AT00937527T patent/ATE383153T1/de active
- 2000-05-05 EP EP00937527A patent/EP1176956B1/en not_active Expired - Lifetime
- 2000-05-05 WO PCT/US2000/012303 patent/WO2000067746A1/en not_active Ceased
- 2000-05-05 SI SI200020021A patent/SI20744B/sl not_active IP Right Cessation
- 2000-05-05 RU RU2001133360/04A patent/RU2263109C2/ru not_active IP Right Cessation
- 2000-05-05 TR TR2002/01920T patent/TR200201920T2/tr unknown
- 2000-05-05 JP JP2000616772A patent/JP5132855B2/ja not_active Expired - Fee Related
- 2000-05-05 CZ CZ20013963A patent/CZ303312B6/cs not_active IP Right Cessation
- 2000-05-05 NZ NZ515248A patent/NZ515248A/xx not_active IP Right Cessation
- 2000-05-05 RO ROA200101210A patent/RO122246B1/ro unknown
- 2000-05-05 CA CA2373360A patent/CA2373360C/en not_active Expired - Lifetime
- 2000-05-05 DE DE60037726T patent/DE60037726T2/de not_active Expired - Lifetime
- 2000-05-05 DK DK00937527T patent/DK1176956T3/da active
- 2000-05-05 MX MXPA01011340A patent/MXPA01011340A/es active IP Right Grant
- 2000-05-05 PL PL351396A patent/PL205322B1/pl unknown
- 2000-05-05 TR TR2001/03178T patent/TR200103178T2/tr unknown
- 2000-05-05 ES ES00937527T patent/ES2296625T3/es not_active Expired - Lifetime
- 2000-05-05 SK SK1608-2001A patent/SK286696B6/sk not_active IP Right Cessation
- 2000-05-05 IL IL14631100A patent/IL146311A0/xx active IP Right Grant
- 2000-11-16 IN IN1110KON2001 patent/IN2001KN01110A/en unknown
-
2001
- 2001-10-24 ZA ZA200108774A patent/ZA200108774B/en unknown
- 2001-11-01 IL IL146311A patent/IL146311A/en not_active IP Right Cessation
- 2001-11-06 NO NO20015418A patent/NO324421B1/no not_active IP Right Cessation
-
2008
- 2008-03-05 CY CY20081100253T patent/CY1107438T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200103178T2 (tr) | İntegrinlerin reseptörlere bağlanmasını engelleyen karboksilik asit türevleri. | |
| TR200103179A2 (tr) | Integrinlerin reseptörlerine bağlanmasını engelleyen karboksilik asit türevleri | |
| PL346220A1 (en) | Compounds that inhibit the binding of integrins to their receptors | |
| ATE420876T1 (de) | Propansäurederivate die die bindung von integrinen an ihre rezeptoren hemmen | |
| IL146312A0 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors | |
| AU2323897A (en) | Cyclopropyl alkanoic acid derivatives | |
| CA2361285A1 (en) | Propanoic acid derivatives that inhibit the binding of integrins to their receptors |